Changes of liver fibrosis markers in patients with treatment by antiviral therapy

Hidekazu Ishidalr, Atsushi Suetsugu, Nobuyuki Furuta, Yuzuru Nohisa, Masao Takemura, Kuniaki Saito, Yohei Shirakam, Hiroyasu Itou

Research output: Contribution to journalArticle

Abstract

Recently, most patients with chronic hepatitis C have become possible to achieve sustained virological response (SVR) due to progress of antiviral therapy. However, risk of hepatic carcinoma remains even after SVR. Liver fibrosis is one of most important risk factors of hepatic carcinoma, and it is necessary to evaluate the progression of liver fibrosis. Although liver biopsy has been used for diagnostics of liver fibrosis, it is difficult to perform frequently because of serious invasive complication. Recently, the novel liver fibrosis markers such as M2BPGi was developed using serum. We examined the alteration of liver fibrosis markers, Mac-2 binding protein glycosylation isomer (M2BPG0 and Enhanced Liver Fibrosis (ELF) score, in the patients with antiviral therapy for chronic hepatitis C. Serum M2BPGi levels and ELF score was correlated with fibrosis stages evaluated by histological examination. Moreover, measurement of M2BPGi levels and ELF score higher diagnostic ability compared to the number of platelets. In addition, serum M2BPGi levels and ELF score were significantly increased after pegylated-interferon therapy. It showed that serum M2BPGi levels and ELF score are different variation depending on antiviral therapy. The alteration of serum M2BPGi levels and ELF score was depend on antiviral therapies. We concluded that it is necessary to reveal usefulness as monitoring marker for hepatic carcinoma in patients with SVR.

Original languageEnglish
Pages (from-to)137-143
Number of pages7
JournalJapanese Journal of Clinical Chemistry
Volume48
Issue number2
Publication statusPublished - 01-04-2019

Fingerprint

Liver Cirrhosis
Liver
Antiviral Agents
Therapeutics
Serum
Chronic Hepatitis C
Carcinoma
Glycosylation
Biopsy
Platelet Count
Platelets
Interferons
Isomers
Carrier Proteins
Fibrosis
Monitoring

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

Ishidalr, H., Suetsugu, A., Furuta, N., Nohisa, Y., Takemura, M., Saito, K., ... Itou, H. (2019). Changes of liver fibrosis markers in patients with treatment by antiviral therapy. Japanese Journal of Clinical Chemistry, 48(2), 137-143.
Ishidalr, Hidekazu ; Suetsugu, Atsushi ; Furuta, Nobuyuki ; Nohisa, Yuzuru ; Takemura, Masao ; Saito, Kuniaki ; Shirakam, Yohei ; Itou, Hiroyasu. / Changes of liver fibrosis markers in patients with treatment by antiviral therapy. In: Japanese Journal of Clinical Chemistry. 2019 ; Vol. 48, No. 2. pp. 137-143.
@article{5dead42953104459a626a824679190e1,
title = "Changes of liver fibrosis markers in patients with treatment by antiviral therapy",
abstract = "Recently, most patients with chronic hepatitis C have become possible to achieve sustained virological response (SVR) due to progress of antiviral therapy. However, risk of hepatic carcinoma remains even after SVR. Liver fibrosis is one of most important risk factors of hepatic carcinoma, and it is necessary to evaluate the progression of liver fibrosis. Although liver biopsy has been used for diagnostics of liver fibrosis, it is difficult to perform frequently because of serious invasive complication. Recently, the novel liver fibrosis markers such as M2BPGi was developed using serum. We examined the alteration of liver fibrosis markers, Mac-2 binding protein glycosylation isomer (M2BPG0 and Enhanced Liver Fibrosis (ELF) score, in the patients with antiviral therapy for chronic hepatitis C. Serum M2BPGi levels and ELF score was correlated with fibrosis stages evaluated by histological examination. Moreover, measurement of M2BPGi levels and ELF score higher diagnostic ability compared to the number of platelets. In addition, serum M2BPGi levels and ELF score were significantly increased after pegylated-interferon therapy. It showed that serum M2BPGi levels and ELF score are different variation depending on antiviral therapy. The alteration of serum M2BPGi levels and ELF score was depend on antiviral therapies. We concluded that it is necessary to reveal usefulness as monitoring marker for hepatic carcinoma in patients with SVR.",
author = "Hidekazu Ishidalr and Atsushi Suetsugu and Nobuyuki Furuta and Yuzuru Nohisa and Masao Takemura and Kuniaki Saito and Yohei Shirakam and Hiroyasu Itou",
year = "2019",
month = "4",
day = "1",
language = "English",
volume = "48",
pages = "137--143",
journal = "Japanese Journal of Clinical Chemistry",
issn = "0370-5633",
publisher = "Japanese Journal of Clinical Chemistry",
number = "2",

}

Ishidalr, H, Suetsugu, A, Furuta, N, Nohisa, Y, Takemura, M, Saito, K, Shirakam, Y & Itou, H 2019, 'Changes of liver fibrosis markers in patients with treatment by antiviral therapy', Japanese Journal of Clinical Chemistry, vol. 48, no. 2, pp. 137-143.

Changes of liver fibrosis markers in patients with treatment by antiviral therapy. / Ishidalr, Hidekazu; Suetsugu, Atsushi; Furuta, Nobuyuki; Nohisa, Yuzuru; Takemura, Masao; Saito, Kuniaki; Shirakam, Yohei; Itou, Hiroyasu.

In: Japanese Journal of Clinical Chemistry, Vol. 48, No. 2, 01.04.2019, p. 137-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changes of liver fibrosis markers in patients with treatment by antiviral therapy

AU - Ishidalr, Hidekazu

AU - Suetsugu, Atsushi

AU - Furuta, Nobuyuki

AU - Nohisa, Yuzuru

AU - Takemura, Masao

AU - Saito, Kuniaki

AU - Shirakam, Yohei

AU - Itou, Hiroyasu

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Recently, most patients with chronic hepatitis C have become possible to achieve sustained virological response (SVR) due to progress of antiviral therapy. However, risk of hepatic carcinoma remains even after SVR. Liver fibrosis is one of most important risk factors of hepatic carcinoma, and it is necessary to evaluate the progression of liver fibrosis. Although liver biopsy has been used for diagnostics of liver fibrosis, it is difficult to perform frequently because of serious invasive complication. Recently, the novel liver fibrosis markers such as M2BPGi was developed using serum. We examined the alteration of liver fibrosis markers, Mac-2 binding protein glycosylation isomer (M2BPG0 and Enhanced Liver Fibrosis (ELF) score, in the patients with antiviral therapy for chronic hepatitis C. Serum M2BPGi levels and ELF score was correlated with fibrosis stages evaluated by histological examination. Moreover, measurement of M2BPGi levels and ELF score higher diagnostic ability compared to the number of platelets. In addition, serum M2BPGi levels and ELF score were significantly increased after pegylated-interferon therapy. It showed that serum M2BPGi levels and ELF score are different variation depending on antiviral therapy. The alteration of serum M2BPGi levels and ELF score was depend on antiviral therapies. We concluded that it is necessary to reveal usefulness as monitoring marker for hepatic carcinoma in patients with SVR.

AB - Recently, most patients with chronic hepatitis C have become possible to achieve sustained virological response (SVR) due to progress of antiviral therapy. However, risk of hepatic carcinoma remains even after SVR. Liver fibrosis is one of most important risk factors of hepatic carcinoma, and it is necessary to evaluate the progression of liver fibrosis. Although liver biopsy has been used for diagnostics of liver fibrosis, it is difficult to perform frequently because of serious invasive complication. Recently, the novel liver fibrosis markers such as M2BPGi was developed using serum. We examined the alteration of liver fibrosis markers, Mac-2 binding protein glycosylation isomer (M2BPG0 and Enhanced Liver Fibrosis (ELF) score, in the patients with antiviral therapy for chronic hepatitis C. Serum M2BPGi levels and ELF score was correlated with fibrosis stages evaluated by histological examination. Moreover, measurement of M2BPGi levels and ELF score higher diagnostic ability compared to the number of platelets. In addition, serum M2BPGi levels and ELF score were significantly increased after pegylated-interferon therapy. It showed that serum M2BPGi levels and ELF score are different variation depending on antiviral therapy. The alteration of serum M2BPGi levels and ELF score was depend on antiviral therapies. We concluded that it is necessary to reveal usefulness as monitoring marker for hepatic carcinoma in patients with SVR.

UR - http://www.scopus.com/inward/record.url?scp=85072165539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072165539&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85072165539

VL - 48

SP - 137

EP - 143

JO - Japanese Journal of Clinical Chemistry

JF - Japanese Journal of Clinical Chemistry

SN - 0370-5633

IS - 2

ER -

Ishidalr H, Suetsugu A, Furuta N, Nohisa Y, Takemura M, Saito K et al. Changes of liver fibrosis markers in patients with treatment by antiviral therapy. Japanese Journal of Clinical Chemistry. 2019 Apr 1;48(2):137-143.